trial

Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia

NCTId NCT01391403
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 88 (actual)
Sponsored by Beijing HuiLongGuan Hospital
Primary completion 2011-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
88 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-09
Primary completion
2011-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Artemisinin

Sponsors

Beijing HuiLongGuan HospitalLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Lian Y Cao, MDStudy Chair

Sites

1 total
Beijing, China

Linked catalysts

1
Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia — primary completion2011-04

Facts & assertions

4 sourced
Enrollment
88
Phase
PHASE3
Primary Completion Date
2011-04
Status
COMPLETED
relationships
The graph out of here
drug
Artemisinin
drug
lead_sponsor
Beijing HuiLongGuan Hospital
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lian Y Cao, MD
person